Bibliographical noteFunding Information:
J.L. Calleja reports consultancy and speaker fees from Echosens, Advanz Ph, and MSD, outside of the submitted work. K. Cusi is a consultant for Altimmune, Akero, Arrowhead, AstraZeneca, 89Bio, BMS, Coherus, Intercept, Lilly, Madrigal, Merck, Novo Nordisk, Quest, Sagimet, Sonic Incytes, Terns, Thera Technologies, and MSD, outside of the submitted work. J.F. Dillon has received research grants and lecture honoraria from MSD , AbbVie, and Gilead , outside of the submitted work. M.L. Martínez-Chantar advises for Mitotherapeutix LCC, outside of the submitted work. J.M. Schattenberg reports consultancy for Apollo Endosurgery, Albireo Pharma Inc, Bayer, BMS, Boehringer Ingelheim, Echosens, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Madrigal, MSD, Nordic Bioscience, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthcare GmbH and research Funding from Gilead Sciences , Boehringer Ingelheim , Nordic Bioscience , and Siemens Healthcare GmbH , outside of the submitted work. J. Crespo reports consulting and personal fees from Gilead Sciences, AbbVie, MSD, Shionogi, Intercept Pharmaceuticals, Janssen Pharmaceuticals Inc, Celgene, and Alexion, outside of the submitted work. J.V. Lazarus acknowledges grants and speaker fees from AbbVie, Gilead Sciences, and MSD and speaker fees from Genfit, Intercept, Janssen, Novo Nordisk, and ViiV, outside of the submitted work. P. Iruzubieta, R. Bataller, M.T. Arias-Loste, M. Arrese, G. Castro-Narro, M. Mateo, A. Pérez, M.E. Rinella, M. Romero-Gómez, and S. Zelber-Sagi have nothing to disclose.
The authors acknowledge the Valdecilla Biomedical Research Institute (Santander, Spain) for supporting the International Precision Medicine Forum: NAFLD Updated. J.V. Lazarus acknowledges institutional support to ISGlobal from the Spanish Ministry of Science , Innovation and Universities, through the “Centro de Excelencia Severo Ochoa 2019 to 2023” Program ( CEX2018-000806-S ), and from the Government of Catalonia , Spain, through the CERCA Programme. Funding from the Spanish Instituto de Salud Carlos III Grant (FIS - PI18/01304 to J. Crespo) and from the Agencia Nacional de Investigación y Desarrollo ( ANID) , Chile (to M. Arrese) is also acknowledged.
- Disease phenotyping
- Multidisciplinary care
- Non-invasvie tests (NITs)
- Precision medicine
ASJC Scopus subject areas